St Shared Services LLC DBA Keenova Therapeutics (FKA St Shared Services LLC DBA
Based in MO
🤖
AI Overview
With $8.4M in lobbying spend across 35 quarterly filings, St Shared Services LLC DBA Keenova Therapeutics (FKA St Shared Services LLC DBA is one of the biggest lobbying spenders in Washington. Their lobbying covers 6 issue areas. Active from 2018 to 2025.
$8.4M
Total Spend
8
Years Active
1
Firms Hired
3
Lobbyists Deployed
6
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $1.6M |
| 2019 | $820K |
| 2020 | $1.6M |
| 2021 | $1.3M |
| 2022 | $1.0M |
| 2023 | $680K |
| 2024 | $770K |
| 2025 | $640K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Copyright/Patent, Health Issues, Pharmacy, Medicare/Medicaid, Budget/Appropriations and 1 more
- •Innovation ACT (H.R.9); Issues related to patents.
- •Issues related to Medicare and opioids; Issues related to BARDA funding; Appropriations
- •21st Century CURES Act (H.R.6); Issues related to "real world" clinical evidence; Issues related to Opioid abuse and alternatives to opioids (no specific bill number); Issues related to Medicare and M
- •340B (no specific bill); Issues related to Medicare generally.
Related Analysis
Related Investigations
Big Tech's $150M Lobbying War
Tech giants battle over AI, antitrust, privacy, and trade.
Who's Lobbying to Shape AI Policy
The AI regulation fight is the biggest lobbying battle of the decade.
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
The 22,000% ROI
When lobbying spending yields outsized returns.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.